Objective: To observe the effect of Tongqiao Huoxuefang combined with flunarizine on the prognosis of Qixu Xueyu type ischemic stroke patients. Method: A total of 100 ischemic stroke patients treated in our hospital January 2015 to June 2016 were randomly divided into control group (30 cases)

and treatment A and B groups (35 cases in each group)

and 50 health cases were selected into the control group. Patients in control group were treated with antiplatelet and anticoagulant treatment; in addition to the therapy of control group

treatment A and B groups were also treated with Tongqiao Huoxuefang alone as well as Tongqiao Huoxuefang combined with flunarizine. The symptom score

National Institute of Health Stroke Scale (NIHSS) score

infarct volume

clinical efficacy

max platelet aggregation rate (MAR)

living ability (IADL score) and quality of life (SS-QOL)

serum calcium and calmodulin kinase Ⅱ (CaMKⅡ) levels were compared and analyzed. Kaplan-Meier survival curves were drawn to compare the differences in the prognosis (improved Rankin scale)

living ability (IADL score) and quality of life (SS-QOL) between the two groups

and explore CaMKⅡ-based efficacy and long-term prognosis after treatment. Result: After treatment

the scores of NIHSS and infarct volume were significantly lower than those before treatment

and the treatment group B was more obvious (P<0.05) than that in group A after 4 weeks of treatment (P<0.05). After 2 months of treatment

the living ability and quality of life in treatment A and B groups were significantly higher than those of the control group. Among them

treatment group B after 4 months of treatment was more obvious than group A (P<0.05). There was no significant difference in the total effective rate and the good prognosis rate in the treatment groups

but they were higher than those in control group. CaMKⅡ and MAR in control group and the treatment groups were significantly lower than those before treatment

and Ca2+ level was significantly higher

particularly in treatment group B (P<0.05). Conclusion: Tongqiao Huoxuefang combined with flunarizine have a better prognosis in the treatment of ischemic stroke

and can significantly alleviate the patient's neurological impairment and improve the living ability and quality of life. CaMKⅡ shows a higher predictive efficacy and long-term prognosis.